Oxidative stress and inflammation have been recognized as important contributors to the risk
of chronic non-communicable diseases. Polyunsaturated fatty acids (PUFAs) may regulate …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

Cardiovascular disease (CVD) is the leading cause of death in the United States and
worldwide. A major risk factor for this condition is increased serum low-density lipoprotein …

Adding to the foundation of statins, ezetimibe and proprotein convertase subtilisin–kexin
type 9 inhibitors (PCSK9i), novel, emerging low-density lipoprotein cholesterol (LDL-C) …

When secreted into the circulation, proprotein convertase subtilisin kexin type 9 (PCSK9)
blocks the low-density lipoprotein receptors (LDL-R) and, as a consequence, low-density …

Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-density
lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDLR) …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a clinically validated target for
treating cardiovascular disease (CVD) due to its involvement in cholesterol metabolism …

EGFR mutations are an ongoing challenge in the treatment of NSCLC, and demand
continuous updating of EGFR TKI drug candidates. Pyrrolopyrimidines are one group of …

Atherosclerosis is a primary precursor of cardiovascular disease (CVD), the leading cause of
death worldwide. While proprotein convertase subtilisin/kexin 9 (PCSK9) contributes to CVD …